Michail_Petrov-96/iStock via Getty Images Lexaria (NASDAQ:LEXX) said it plans to run an animal study evaluating formulations of its products DehydraTECH-GLP-1, which includes Novo Nordisk's semaglutide or liraglutide, and DehydraTECH-CBD in the treatment of weight loss and diabetes. DehydraTECH-GLP-1 is a GLP-1 drug processed with the company’s DehydraTECH drug delivery technology, while DehydraTECH-CBD is a cannabidiol product.

Michail\u Petrov-96/iStock通过Getty Images Lexaria（纳斯达克：LEXX）表示，计划进行一项动物研究，评估其产品Deterhetech-GLP-1的配方，其中包括诺和诺德的semaglutide或利拉鲁肽，以及Deterhetech CBD治疗减肥和糖尿病。脱水技术-GLP-1是一种GLP-1药物，采用该公司的脱水技术药物输送技术进行处理，而脱水技术-CBD是大麻二酚产品。

The company will be testing the products alone and in combination for weight loss and blood glucose level control, according to a statement. Lexaria said the GLP-1 formulations to be tested will include Novo Nordisk’s (NVO) semaglutide or liraglutide. Semaglutide is marketed by Novo Nordisk under the names Wegovy, Ozempic and Rybelsus.

根据一份声明，该公司将单独或联合测试这些产品的减肥和血糖水平控制。Lexaria表示，要测试的GLP-1制剂将包括诺和诺德（Novo Nordisk）的semaglutide或利拉鲁肽。Semaglutide由诺和诺德以Wegovy，Ozempic和Rybelsus的名称销售。

Liraglutide is sold under the names Victoza and Saxenda. More on Lexaria Bioscience Corp. Lexaria slips despite FDA nod to test blood pressure drug Lexaria submits IND to begin Phase 1b study of DehydraTECH-CBD Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical earnings data for Lexaria Bioscience Corp.

利拉鲁肽以维克托萨和萨森达的名字出售。关于Lexaria Bioscience Corp.的更多信息。Lexaria下滑，尽管FDA批准测试血压药物Lexaria提交IND开始脱水技术CBD的1b期研究，寻求Lexaria Bioscience Corp.的Alpha定量评级。Lexaria Bioscience Corp.的历史收益数据。

Financial information for Lexaria Bioscience Corp. .

Lexaria Bioscience Corp.的财务信息。